Atlas Trials

Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders

Clinical trial NCT00992732 · TERMINATED

Trial details

NCT number
NCT00992732
Sponsor
HemaQuest Pharmaceuticals Inc.
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Lymphoid MalignanciesLymphoproliferative Disorders
Start date
2010-05-01
Primary completion
2010-11-01
Enrollment
1

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.